Tenax Therapeutics Inc (NASDAQ:TENX)’s share price shot up 7.6% during trading on Wednesday . The stock traded as high as $1.68 and last traded at $1.55, 404,932 shares were traded during trading. A decline of 40% from the average session volume of 675,102 shares. The stock had previously closed at $1.44.
Separately, ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.
The company has a debt-to-equity ratio of 0.01, a current ratio of 11.04 and a quick ratio of 11.04. The stock has a market cap of $8.73 million, a PE ratio of -0.17 and a beta of 1.41. The firm’s 50-day moving average price is $1.35.
An institutional investor recently bought a new position in Tenax Therapeutics stock. Bank of New York Mellon Corp bought a new position in shares of Tenax Therapeutics Inc (NASDAQ:TENX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 38,077 shares of the specialty pharmaceutical company’s stock, valued at approximately $46,000. Bank of New York Mellon Corp owned 2.59% of Tenax Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 16.29% of the company’s stock.
About Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.